CELLDEX THERAPEUTICS INC NEW's ticker is and the CUSIP is 15117B953. A total of 3 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $17,000 | -77.6% | 33,700 | +3.1% | 0.00% | -100.0% |
| Q1 2018 | $76,000 | -78.2% | 32,700 | -73.4% | 0.00% | -50.0% |
| Q4 2017 | $349,000 | +501.7% | 122,900 | +502.5% | 0.00% | +100.0% |
| Q3 2017 | $58,000 | -68.6% | 20,400 | -72.7% | 0.00% | -50.0% |
| Q2 2017 | $185,000 | -5.6% | 74,700 | +37.3% | 0.00% | 0.0% |
| Q1 2017 | $196,000 | -47.5% | 54,400 | -48.4% | 0.00% | -50.0% |
| Q4 2016 | $373,000 | -37.1% | 105,500 | -28.1% | 0.00% | -33.3% |
| Q3 2016 | $593,000 | -13.7% | 146,800 | -6.3% | 0.01% | -25.0% |
| Q2 2016 | $687,000 | +28.9% | 156,600 | +11.0% | 0.01% | 0.0% |
| Q1 2016 | $533,000 | -93.0% | 141,100 | -70.8% | 0.01% | -91.1% |
| Q4 2015 | $7,573,000 | +2.4% | 483,000 | -31.2% | 0.09% | -11.8% |
| Q3 2015 | $7,397,000 | -67.5% | 701,800 | -22.2% | 0.10% | -67.9% |
| Q2 2015 | $22,743,000 | +4.8% | 901,800 | +15.9% | 0.32% | -6.7% |
| Q1 2015 | $21,694,000 | +186.8% | 778,400 | +87.8% | 0.34% | +199.1% |
| Q4 2014 | $7,565,000 | +109.4% | 414,500 | +48.7% | 0.11% | +103.6% |
| Q3 2014 | $3,613,000 | -42.8% | 278,800 | -27.9% | 0.06% | -42.3% |
| Q2 2014 | $6,314,000 | +5.6% | 386,900 | +14.3% | 0.10% | -4.0% |
| Q1 2014 | $5,981,000 | +5.9% | 338,500 | +45.2% | 0.10% | +18.8% |
| Q4 2013 | $5,646,000 | -23.9% | 233,200 | +11.4% | 0.08% | -40.1% |
| Q3 2013 | $7,416,000 | +411.8% | 209,300 | +125.5% | 0.14% | +294.4% |
| Q2 2013 | $1,449,000 | – | 92,800 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 688 | $1,666,000 | 0.11% |
| GROUP ONE TRADING, L.P. | 233,200 | $5,646,000 | 0.08% |
| Citadel Advisors | 83,700 | $2,026,000 | 0.00% |